| FDA Panel Votes in Favor of Renal Cell Carcinoma Drug - MedPage Today |
|
|
MedPage Today The vote came after several hours of discussion about Pfizer's 723-patient trial, which showed that renal cell carcinoma patients who had previously received sunitinib treatment for their advanced renal cancer (a group that includes most patients with ... FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In |